The selection of biological agents for rheumatism arthritis The rheumatitis arthritis (RA) is a chronic, self-immunological disease, manifested mainly in joint pain, swelling and rigidity. The treatment of rheumatism-type arthritis includes general treatment, medication and surgical treatment, in which biological agents, as a new form of treatment, have been widely used clinically in recent years. This paper will explore the selection of biological agents for rheumatitis. # I. Types of biological agents Biological agents can be specific to key target points in the rheumatological arthritis outbreak mechanism, such as tumour necrosis chordal α (TNF-α), white cell media 6 receptor (IL-6R), so as to function more precisely to effectively contain inflammatory reactions and mitigate symptoms. The main types of biological agents currently used are the following: They achieve therapeutic purposes by inhibiting the inflammation of TNF-α.
2. White medium-6 receptor resistance, i.e., the monotony resistance (Amero), which achieves therapeutic purposes by reducing IL-6 levels and inhibiting their inflammation.
3. Other biological agents, including white-media-1 receptor stressor (Ana-Bedin), T-cell co-stimulant retardant (Abasap), B-cell depletion agent (Lituto-silent).
Small molecular target medications, such as JAK inhibitors (Tofateb, Bariteni), whose effects are similar to those of biological agents injected under traditional skins but require daily oral treatment. 1. Individualized treatment: The symptoms, pathology, severity, etc. of patients with rheumatism-like arthritis vary, so that the selection of suitable biological agents should be based on the patient ‘ s specific circumstances. 2. Co-therapy: Biological agents are usually used in combination with traditional slow-activated anti-retardants (e.g., ammonium butterflies, fluoromettes, etc.) to treat rheumatism. 3. Assessing the condition of patients: Before applying biological agents, potential diseases such as tumours, hepatitis and tuberculosis need to be eliminated and screening for infections, tumours, etc. is required to determine whether the patient is fit to apply biological agents. 4. Consideration of side effects: Biological agents may cause side effects such as infections, tumours, rashes, gastrointestinal reaction, damage to liver and kidney function, and should be monitored regularly for blood routines, liver and kidney function, timely detection and treatment. 5. Economic affordability: The cost of biological agents is relatively high and patients should make reasonable choice of treatment, taking into account their own financial affordability.
The frequency of use of a biological agent varies from one biological agent to another. For example, it may be used twice a week (injecting recapacitator II tumour necrosis receptor integrated proteins); it may be used once every two weeks in Adamu; and some drugs may be used once a month. The specific frequency of use should be adjusted to the recommended dose in the drug instructions, as well as the patient ‘ s condition and tolerance.
The efficacy and safety of biological agents The efficacy of biological agents in treating rheumatism arthritis is positive and can be shown in a relatively short period of time, helping patients to quickly reduce the discomfort of their joint pains, swelling, etc., and improving their function and quality of life. At the same time, there is a degree of safety for biological agents, which, although there may be some side effects, are generally relatively more resistant. Reasonable monitoring and management can reduce the occurrence of adverse effects and guarantee the safety of treatment. # V. Summarizing that the selection of biological agents for rheumatism arthritis should be individualized according to the patient ‘ s circumstances, taking into account such factors as joint treatment, assessment of the patient ‘ s condition, consideration of side effects and financial affordability. During drug use, changes in the patient ‘ s condition and side effects should be closely monitored and treatment programmes adjusted in a timely manner. Through the treatment of reasonable biological agents, the condition of persons with rheumatism arthritis can be effectively controlled and the quality of life improved.
